DARA Biosciences Inc  

(Public, NASDAQ:DARA)   Watch this stock  
Find more results for Timothy J. Irons´┐Ż
0.845
0.000 (0.00%)
Sep 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.67 - 1.26
Open     -
Vol / Avg. 0.00/105,752.00
Mkt cap 16.69M
P/E     -
Div/yield     -
EPS -0.49
Shares 19.76M
Beta 0.87
Inst. own 9%
Nov 3, 2015
Q3 2015 DARA BioSciences Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
DARA BioSciences Inc at Rodman & Renshaw Global Investment Conference - 9:35AM EDT - Add to calendar
Aug 13, 2015
Q2 2015 DARA BioSciences Inc Earnings Call
Aug 12, 2015
Q2 2015 DARA BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -270.90% -489.66%
Operating margin -270.90% -498.28%
EBITD margin - -464.49%
Return on average assets -80.84% -71.77%
Return on average equity -108.51% -87.71%
Employees 15 -
CDP Score - -

Address

8601 Six Forks Rd Ste 160
RALEIGH, NC 27615-2965
United States - Map
+1-816-9147027 (Phone)
+1-919-8610239 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DARA BioSciences, Inc. is a specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy.

Officers and directors

David J. Drutz M.D. Executive Chairman of the Board, Chief Medical Officer
Age: 76
Bio & Compensation  - Reuters
Christopher G. Clement President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Haywood D. Cochrane Jr. Independent Vice Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
David L. Tousley Acting Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Timothy J. Heady Independent Director
Age: 60
Bio & Compensation  - Reuters
Gail F. Lieberman Independent Director
Age: 71
Bio & Compensation  - Reuters
Paul J. Richardson Independent Director
Age: 58
Bio & Compensation  - Reuters